Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.250
-0.090 (-2.07%)
At close: Sep 11, 2026, 4:00 PM EDT
4.590
+0.340 (8.00%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Camp4 Therapeutics Revenue
Camp4 Therapeutics had revenue of $1.78M in the quarter ending June 30, 2026, with 18.84% growth. This brings the company's revenue in the last twelve months to $4.22M, up 40.21% year-over-year. In the year 2025, Camp4 Therapeutics had annual revenue of $3.50M with 436.50% growth.
Revenue (ttm)
$4.22M
Revenue Growth
+40.21%
P/S Ratio
63.26
Revenue / Employee
$87,833
Employees
48
Market Cap
266.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.50M | 2.85M | 436.50% |
| Dec 31, 2024 | 652.00K | 302.00K | 86.29% |
| Dec 31, 2023 | 350.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CAMP News
- 3 days ago - CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - GlobeNewsWire
- 4 days ago - Camp4 Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 days ago - CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 - GlobeNewsWire
- 12 days ago - CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Camp4 Therapeutics reports Q2 EPS (58c), consensus (21c) - TheFly
- 4 weeks ago - Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler - TheFly
- 4 weeks ago - CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 4 weeks ago - Camp4 Therapeutics Quarterly report: Q2 2026 - Filings